EDE’s 9 September Korea visit puts CGT pathway on UAE pharmacy agenda

Emirates Drug Establishment (EDE) officials visited Biosolution and Helixmith in Seoul to discuss cell and gene therapy (CGT) cooperation, according to Korea Biomedical Review on 9 September 2026.

The highest-stakes readers are COOs, CFOs and medical directors. For Dubai providers licensed by the Dubai Health Authority (DHA), the near-term issue is readiness for referral, storage, consent and pharmacovigilance pathways. For Abu Dhabi and Al Ain, the same question sits with the Department of Health Abu Dhabi (DOH Abu Dhabi). In Sharjah, Ajman, Umm Al Quwain, Ras Al Khaimah and Fujairah, facility oversight remains tied to the Ministry of Health and Prevention (MOHAP), while EDE controls federal medical product regulation.

What EDE discussed in Korea

Korea Biomedical Review reported that the head of the UAE pharmaceutical regulator visited Biosolution and Helixmith’s research centre in Seoul to discuss regulatory cooperation and possible market entry. A separate EDAILY report said Dr. Fatima Al Kaabi, Director General of EDE, was in South Korea on 8 September 2026 to receive briefings from Korean CGT companies.

The Korean companies named in the wider roundtable included Bio Solution Co., Ltd., Helixmith Co., Ltd., ORGANOIDSCIENCES LTD., CORESTEMCHEMON and Chabiotech Co., Ltd.. Their pipelines cover cell therapies, gene therapies, stem cell therapies, NK cell therapies and organoid-based regenerative therapies.

Helixmith gives the UAE a case study in late-stage gene therapy development. EDAILY reported that NL003, a VM202-based gene therapy licensed to China’s Northland Biotech, received marketing authorisation from China’s National Medical Products Administration in May 2026 for critical limb ischemia. Biosolution brings a different profile, with commercialised autologous cartilage cell therapy in Korea and work on allogeneic and injectable cell therapy candidates.

Why UAE operators should care

The commercial signal is access, rather than immediate volume. EDE’s own portal says the authority was established on 29 September 2023 and is responsible for regulating pharmaceutical products, medical devices, blood derivatives, stem cells and genetically modified organisms. That puts CGT market authorisation, pharmacovigilance and product controls in one federal channel.

UAE operators already have a precedent. The Emirates News Agency reported on 28 March 2025 that EDE granted market authorisation for CASGEVY, a CRISPR/Cas9 gene-editing therapy, for patients aged 12 years and older with sickle cell disease with recurrent vaso-occlusive crises, and for transfusion-dependent thalassemia. DOH Abu Dhabi announced the UAE launch context in the same report.

For CFOs and insurers, the practical issue is benefit design. Public list prices for many one-time CGTs are set in the United States or Europe, then negotiated locally. Published international launch prices often sit in the multimillion-dirham range after currency conversion. UAE finance teams should ask manufacturers and distributors for four documents before budgeting: EDE authorisation status, UAE registered price, patient eligibility criteria and expected inpatient length of stay.

• DHA clinics should map referral routes to hospital-based infusion or transplant units before marketing CGT access.
• DOH Abu Dhabi providers should check whether registry, genomic testing or outcome reporting requirements apply to each indication.
• MOHAP-licensed providers should verify import, cold-chain and dispensing permissions before accepting patient referrals.
• Insurers such as Daman, Thiqa and Sukoon should separate drug cost, admission cost, ICU contingency and long-term monitoring in pre-authorisation rules.

What changes for clinics, insurers and patients

CGT is operationally different from routine specialty pharmacy. Eligibility usually depends on a confirmed diagnosis, genetic or cellular testing, prior treatment history and organ-function thresholds. A clinic cannot infer coverage from an overseas approval. It needs EDE product status, the emirate-level facility licence and payer approval in the same patient file.

Patients will feel the change through referrals and waiting time. A Dubai outpatient clinic may identify a candidate, but administration may sit in an Abu Dhabi tertiary centre or an overseas partner site until local capacity is listed. Families will ask about cost before science. Providers should answer with a written estimate that separates screening, product acquisition, procedure, admission and follow-up.

The next watch point is whether EDE turns the Korean talks into a reliance, trial or early-access pathway for specific products. Operators should track EDE notices, DHA circulars, DOH Abu Dhabi standards and MOHAP facility guidance through Q4 2026. For licensed pharmacy providers, readers can use the UAE Open Healthcare Directory to find licensed pharmacy providers by emirate and service type.